Compare ORBS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORBS | IFRX |
|---|---|---|
| Founded | 1966 | 2007 |
| Country | United States | Germany |
| Employees | 9 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.0M | 303.4M |
| IPO Year | N/A | 2017 |
| Metric | ORBS | IFRX |
|---|---|---|
| Price | $0.60 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | ★ 11.9M | 1.3M |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.74 |
| 52 Week High | $15.96 | $2.95 |
| Indicator | ORBS | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 36.03 |
| Support Level | N/A | $0.87 |
| Resistance Level | $1.23 | $1.94 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 21.37 | 3.97 |
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.